CAMBRIDGE, Mass., Jul 03, 2014 -- Akashi Therapeutics, Inc. , announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's most advanced product ...

CAMBRIDGE, Mass., July 15, 2013 /PRNewswire/ --DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), has initiated ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc. a clinical stage biopharmaceutical company developing treatments for patients with Duchenne muscular dystrophy (DMD), today reported that ...

With the HT-100, ANAVIA has developed the most advanced unmanned aerial vehicle (UAV) system in the world. An unmanned helicopter for up to 65 kg of payload and 240 minutes of flight time. It’s the ...

The HT-100 is an all-terrain, day/night, adverse-weather-capable unmanned helicopter UAE-based defence-tech group Edge held a capability demonstration for the ANAVIA HT-100 unmanned helicopter within ...

Scale model of HT-100 displayed at IDEX 2025. (Janes/Amit Kalra) Anavia, an Edge Group entity, exhibited a scale model of the naval version of its HT-100 unmanned aerial vehicle (UAV) at the ...

Halo Therapeutics announced that the FDA has granted orphan drug designation for HT-100 (halofuginone) for Duchenne muscular dystrophy (DMD). Plans to initiate a Phase 2 trial in 2012 are underway.

While it’s too late to assemble a proper bug-out bag, we hope for the sake of your easily-pierced flesh that you’ve already bugged—you’re still going to need to grab a few supplies if you want to ...